PB
ALXN

Pinnacle Bancorp’s Alexion Pharmaceuticals ALXN Stock Holding History

Pinnacle Bancorp’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$7K Buy
+61
New +$7.86K ﹤0.01% 539

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Pinnacle Bancorp's ALXN Position: Q1 2017 in Review

Pinnacle Bancorp opened a new position in Alexion Pharmaceuticals (ALXN) in Q1 2017: 61 shares worth $7K. The stake represents ﹤0.01% of the portfolio and ranks #539 among its holdings.

561 funds tracked by Wall St. Rank hold ALXN as of Q1 2017.

  • Pinnacle Bancorp held 61 shares of Alexion Pharmaceuticals worth $7K as of Q1 2017.
  • Alexion Pharmaceuticals was a new Pinnacle Bancorp position in Q1 2017.
  • Alexion Pharmaceuticals made up ﹤0.01% of Pinnacle Bancorp's portfolio in Q1 2017, its #539 holding.
  • 561 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2017.

Based on Pinnacle Bancorp's 13F filing for Q1 2017, filed 17 Apr 2017.